Nuvation Bio (NUVB) Competitors $2.13 -0.01 (-0.23%) Closing price 03:59 PM EasternExtended Trading$2.12 -0.02 (-0.94%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVB vs. CRNX, ALVO, HCM, AMRX, CPRX, BHC, OGN, XENE, MIRM, and IBRXShould you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), HUTCHMED (HCM), AMNEAL PHARMACEUTICALS (AMRX), Catalyst Pharmaceuticals (CPRX), Bausch Health Cos (BHC), Organon & Co. (OGN), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Nuvation Bio vs. Its Competitors Crinetics Pharmaceuticals Alvotech HUTCHMED AMNEAL PHARMACEUTICALS Catalyst Pharmaceuticals Bausch Health Cos Organon & Co. Xenon Pharmaceuticals Mirum Pharmaceuticals ImmunityBio Nuvation Bio (NYSE:NUVB) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Which has better valuation and earnings, NUVB or CRNX? Crinetics Pharmaceuticals has lower revenue, but higher earnings than Nuvation Bio. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M92.31-$567.94M-$2.35-0.91Crinetics Pharmaceuticals$1.04M2,865.62-$298.41M-$3.82-8.33 Do analysts prefer NUVB or CRNX? Nuvation Bio presently has a consensus price target of $7.17, suggesting a potential upside of 235.68%. Crinetics Pharmaceuticals has a consensus price target of $69.50, suggesting a potential upside of 118.35%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Crinetics Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is NUVB or CRNX more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Nuvation Bio's net margin of -5,534.21%. Crinetics Pharmaceuticals' return on equity of -30.95% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Nuvation Bio-5,534.21% -44.14% -32.97% Crinetics Pharmaceuticals N/A -30.95%-28.12% Do institutionals and insiders hold more shares of NUVB or CRNX? 61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 29.9% of Nuvation Bio shares are held by insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, NUVB or CRNX? Nuvation Bio has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Does the media prefer NUVB or CRNX? In the previous week, Crinetics Pharmaceuticals had 8 more articles in the media than Nuvation Bio. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 4 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.64 beat Crinetics Pharmaceuticals' score of 0.42 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryNuvation Bio beats Crinetics Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Nuvation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVB vs. The Competition Export to ExcelMetricNuvation BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$726.46M$2.90B$5.53B$20.56BDividend YieldN/A2.43%4.59%3.64%P/E Ratio-0.9120.2228.5627.18Price / Sales92.31186.60360.9259.81Price / CashN/A41.0524.7317.88Price / Book1.567.618.154.56Net Income-$567.94M-$55.11M$3.24B$995.21M7 Day Performance4.15%7.56%2.01%-0.86%1 Month Performance23.77%11.47%8.27%4.17%1 Year Performance-37.94%0.89%28.39%8.89% Nuvation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVBNuvation Bio3.1852 of 5 stars$2.14-0.2%$7.17+235.7%-37.7%$726.46M$7.87M-0.9160CRNXCrinetics Pharmaceuticals3.4582 of 5 stars$29.06-2.5%$71.75+146.9%-38.5%$2.79B$1.04M0.00210ALVOAlvotech2.8687 of 5 stars$9.02-1.8%$18.00+99.6%-26.7%$2.77B$491.98M15.851,032HCMHUTCHMED1.6274 of 5 stars$15.42-2.5%$19.00+23.2%-16.3%$2.76B$630.20M0.001,811Gap DownAMRXAMNEAL PHARMACEUTICALS2.5803 of 5 stars$8.41-0.1%$11.60+37.9%+17.1%$2.64B$2.79B14.278,100CPRXCatalyst Pharmaceuticals4.9264 of 5 stars$20.95-2.4%$32.83+56.7%+30.4%$2.62B$491.73M9.1780BHCBausch Health Cos3.8101 of 5 stars$6.88-2.5%$7.42+7.8%-14.6%$2.61B$9.63B1.8820,700OGNOrganon & Co.4.8244 of 5 stars$9.74-2.2%$18.00+84.8%-53.9%$2.59B$6.40B2.754,000Trending NewsXENEXenon Pharmaceuticals3.615 of 5 stars$31.83-4.3%$54.82+72.2%-24.0%$2.55B$9.43M0.00210MIRMMirum Pharmaceuticals3.7824 of 5 stars$50.47+0.3%$65.50+29.8%+35.1%$2.49B$336.89M0.00140IBRXImmunityBio2.1786 of 5 stars$2.72flat$12.25+350.4%-56.2%$2.40B$14.74M0.00590 Related Companies and Tools Related Companies Crinetics Pharmaceuticals Alternatives Alvotech Alternatives HUTCHMED Alternatives AMNEAL PHARMACEUTICALS Alternatives Catalyst Pharmaceuticals Alternatives Bausch Health Cos Alternatives Organon & Co. Alternatives Xenon Pharmaceuticals Alternatives Mirum Pharmaceuticals Alternatives ImmunityBio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NUVB) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NUVB Stock Alerts